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This paper provides new insights of how general anaesthetic research should be carried out in the future by an analysis of
what we know, what we do not know and what we would like to know. I describe previous hypotheses on the mechanism of
action of general anaesthetics (GAs) involving membranes and protein receptors. I provide the reasons why the GABA type A
receptor, the NMDA receptor and the glycine receptor are strong candidates for the sites of action of GAs. I follow with a
review on attempts to provide a mechanism of action, and how future research should be conducted with the help of
physical and chemical methods.
Introduction
Generalanaesthetics(GAs)havebeeninusesincethe
mid-19th century. The ﬁrst such drugs were chloro-
form and ether. Over time, more chemicals were
found to have general anaesthetic action. Towards
the middle of the 20th century, the haloalkane
gaseous GAs were synthesized, and they have
remained the family of GA drugs most widely used.
GAscompriseoneofthemostimportantdruggroups
in clinical use. Without them, modern medicine,
especially surgery, would not have been possible.
Although the primary event of GAs is loss of
consciousness, they have additional actions which
include analgesia, amnesia and muscle relaxation.
In this review, I focus mainly on their action as
agents to cause loss of consciousness. I shall ﬁrst
provide a brief review of previous results, concen-
trating on those which have an impact on future
directions. A recent review has discussed the
nervous system pathways involved in greater detail
(Franks, 2008), so the main emphasis here is on
recent progress towards elucidating the molecular
mechanisms of general anaesthesia. I shall also
delineate our ignorance to show how far we are
from a proper understanding of these mechanisms.
Lastly, I provide a ‘road map’ of GA research, to
deﬁne what is needed to complete our understand-
ing of these drugs, and suggest physical and chemi-
cal methods that could potentially revolutionize GA
research at the molecular level.
Background
GAs include a large number of drugs. Nitrous oxide
(N2O) was discovered to have euphorigenic proper-
ties by Humphry Davy as early as 1799, but its GA
properties were only discovered in 1844 by Horace
Wells. Ether and chloroform were introduced at
about the same time. Barbiturates were ﬁrst synthe-
sized in 1864, but their value as GAs was not recog-
nized until 1903. Etomidate, a non-gaseous GA, was
introduced in the 1950s. Halothane was ﬁrst used in
the 1960s; despite the risk of its causing liver
damage in a small number of patients, it is still on
the WHO Essential Drugs List. In the 1970s, the use
of enﬂurane and isoﬂurane became more wide-
spread, propofol came onto the market in the mid-
1980s, and the 1990s saw the rise of sevoﬂurane and
desﬂurane. Figure 1 shows the chemical structures
of some common GAs.
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In pharmacology, speciﬁc binding is very often used
to locate the site of action of a drug. This method,
however, yielded few useful results for gaseous GAs,
because they associate with many proteins non-
speciﬁcally (they bind to more than one sites). Their
EC50 values are mostly of the order of 1 mM, and
experiments have shown that they bind to proteins
as diverse as myoglobin (Schoenborn et al., 1965),
adenylate kinase (Sachsenheimer et al., 1977),
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Diagrams showing the chemical structures of some common GAs.
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albumin (Bhattacharya et al., 2000). The EC50 values
for propofol and etomidate are in the mM ranges, but
propofol binds to protein kinase C (Hemmings and
Adamo, 1994), the nicotinic acetylcholine receptor
(nAChR) (Dilger et al., 1994), the L-type calcium
channel (Zhou et al., 1997) and the g-aminobutyric
acid type A receptor (Hales and Lambert, 1991),
whereas etomidate binds to the 5-hydroxy
tryptamine type 3 receptor (Appadu and Lambert,
1996), the g-aminobutyric acid type A receptor
(Moody et al., 1997) and the a2B-adrenoceptors
(Paris et al., 2003).
For this reason, experiments showing parallelism
of binding and anaesthetic effects are often used.
Indeed, there have been very few studies directly
linking binding to anaesthetic effects. A paper by
Hemmings et al. (2005) listed four criteria for iden-
tifying GA targets: (i) the GA reversibly alters target
function at clinically relevant concentrations. In
experiments not involving whole animals, this
point is of particular importance because a number
of GAs only potentiate the effects of a natural neu-
rotransmitter at clinical doses, but at higher doses
they directly activate the receptor(s); (ii) the target is
expressed in appropriate anatomical locations to
mediate the speciﬁc behavioural effects of the GA;
(iii) the stereo-selective effects of the GA in vivo
parallel actions on the target in vitro; (iv) the target
exhibits appropriate sensitivity (or insensitivity) to
the GAs (or non-GAs). To this, one could add (v) any
drug disrupting the functioning of the target also
abolishes the effect of GAs.
Lipid solubility and pressure reversal
The ﬁrst attempt to explain the effect of GAs came
in about 1900, when Meyer (1899) and Overton
(1901) formulated what became known as the
Meyer–Overton rule which related the hydropho-
bicity of an anaesthetic molecule to its efﬁcacy.
Brieﬂy, their observation suggested that the loga-
rithm of the efﬁcacy of an anaesthetic was related to
the logarithm of its hydrophobicity. Because the
structure of these anaesthetic molecules differed
greatly, a working hypothesis was formulated,
namely there was a uniﬁed mechanism of action for
anaesthetics. In the subsequent 50 years or so,
experimental data on the efﬁcacy of various chemi-
cals, especially homologous organic series, as GAs,
accumulated. The Meyer–Overton rule was found to
be only approximate, and a number of compounds
do not ﬁt the rule e.g. the homologous series of
1-alkanols have greater efﬁcacy than the rule would
predict (Mullins, 1954; Cantor, 2001).
A hint to the mechanism of action of these
agents came with the work of Johnson and Flagler
(1950), who discovered that, by increasing ambient
pressure to 130 atm, anaesthesia by ethanol can be
reversed. Figure 2, from the paper of Johnson and
Flagler (1951), vividly shows this effect. This work
was subsequently extended to Triturus cristatus
carnifex (the Italian crested newt) and the mouse by
Paton and his co-workers, using different GAs (Lever
et al., 1971; Miller et al., 1973), at a pressure of
200 atm. Their results were conﬁrmed by other
researchers at similar pressures (Halsey and Wardley-
Smith, 1975; Youngson and MacDonald, 1975;
Simon et al., 1983; Tonner et al., 1992).
Attempts were made to locate the site of pressure
reversal. Trudell et al. (1973a) performed electron
spin resonance experiments to show that anisotro-
pic motion of phosphatidylcholine within the phos-
Figure 2
Diagrams showing the reaction of Amblyostoma larvae to pressure, in
the presence of 2.5% ethanol. The pressure inside the vessel is shown
in the lower left-hand corner of each panel, 1 psi = 6895 Pa. The six
photographs took place over 4 min. Taken from ﬁgure 2 of Johnson
and Flagler (1951).
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methoxyﬂurane or halothane (anisotropy means
the motion is not the same in all directions). There
was a concomitant decrease of the order parameter
S′n of the phospholipid as the concentration of
anaesthetic increased (Trudell et al., 1973a); the
order parameter can be seen as a measure of the
conformation of the phospholipid non-polar tails.
On application of pressures up to 274 atm by
increasing the amount of helium (a non-anaesthetic
gas at these pressures) in the container, these
changes were reversed: S′n increased and the spectra
shifted back (Trudell et al., 1973b). In subsequent
work, Trudell et al. (1975) studied the effect of
methoxyﬂurane on the mixed dipalmitoyl–
dimyristoylphosphatidyl choline bilayers, and dis-
covered that, at atmospheric pressure, the transition
temperature from the gel phase to the lamellar
smectic liquid crystalline phase was 22.5  0.5°C for
dimyristoylphosphatidylcholine (DMPC), and 40.9
 0.5°C for dipalmitoylphosphatidylcholine. Pres-
sure drives this phase transition to a higher tempera-
ture, but methoxyﬂurane shifts this phase transition
to a lower temperature.
Although the site of pressure reversal appeared
to be the membrane, it was not clear where in the
body this occurred. Pressure reversal was observed
in the action potential in peripheral nerves: high-
pressure helium, itself shown not to affect nerve
conduction, reversed the reduced action potential
height caused by anaesthetics (Roth et al., 1976).
The site of action was not the sympathetic nerves
in the superior cervical ganglion (Kendig et al.,
1975); nor the neuromuscular junction (Kendig
and Cohen, 1976); nor the effect caused by a com-
bination of pentobarbitone, N2O or high-pressure
N2 gas and GABA on its receptors (Little and
Thomas, 1986).
Pressure reversal, although useful as an indicator
of GA action, could never be used as a reliable cri-
terion of GA effect. It was not limited to GAs (Halsey
and Wardley-Smith, 1975); some other compounds
exhibited this effect, and some GAs did not exhibit
pressure reversal (Smith et al., 1984). Lastly, Little
and Thomas (1986) noted that helium gas alone
causes hyperexcitability in the absence of anaesthet-
ics (Halsey, 1982). This gas was sometimes used to
increase the pressure in pressure reversal experi-
ments. Pressure reversal may therefore be a whole-
animal antagonism involving actions at separate
sites, rather than a pharmacological antagonism at
the GA site of action (Little and Thomas, 1986).
Nevertheless, this is a consistently observed prop-
erty of most GAs, so any hypothesis attempting to
explain GA action must also provide a plausible
explanation for these observations.
Stereospeciﬁcity and protein
receptor hypothesis
Further research showed that the effect of GAs was
stereospeciﬁc. Harris et al. (1992) studied the sleep
time induced by S(+)-isoﬂurane and R(-)-isoﬂurane
in mice, and found the (+)-enantiomer induced a
signiﬁcantly longer sleep time in the animals. Lysko
et al. (1994) studied the effect of the same drug on
rats, and found that S(+)-isoﬂurane was 53% more
potent than R(-)-isoﬂurane.
The stereospeciﬁc effects of isoﬂurane could be
consequences of chiral effects of the phospholipid
bilayer. Dickinson et al. (1994) examined the
partition of isoﬂurane enantiomers between a
cholesterol-containing phospholipid bilayer and
water using gas chromatography. They found that
lipid solubilities of the isoﬂurane enantiomers were
essentially identical.
A more functional approach was taken by Tomlin
et al. (1998) who investigated the effect of etomidate
on the righting reﬂex in Rana temporaria tadpoles.
They found that the loss of righting reﬂex EC50 for
R(+)-etomidate was 3.4  0.1 mM, but that for S(-)-
etomidate was 57  1 mM, but the effect of these
enantiomers on the lipid bilayers was identical.
That the stereospeciﬁcity of GAs could not be
accounted for by the membrane made scientists
search for alternatives, and a large number of pro-
teins were suggested as possible targets. Ultimately,
further research has reduced the possibilities down
to a few proteins, which will be discussed in the
following section.
Recent research
One can divide current GA research into different
hierarchical levels. There is work at the molecular
level to delineate the site and mechanism of action,
work at the pathway level to deﬁne the neural
mechanism and work at the whole-animal level to
determine behavioural effects. Here, we are mainly
concerned with molecular-level effects, but I shall
brieﬂy describe results from neural pathway research
which have impact on research at the molecular
level. One can divide recent molecular research into
two broad categories: that which involve the mem-
brane and that which involves a receptor.
Competing hypotheses
The fact that GAs were shown to have non-lipid-
related stereospeciﬁc action gave rise to the idea that
these molecules bind to speciﬁc non-lipid receptors
in the cell (Franks and Lieb, 1984). Four large classes
of protein molecules have been postulated to be the
BJP
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voltage-gated ion channels, enzymes and carrier
proteins. Researchers have tried to link GA effect
with these proteins. So far, persuasive evidence is
available only for two ligand-gated ion channels,
the GABA type A receptor (GABAA receptor, see
subsection GABAA receptors) and the N-methyl-D-
aspartic acid receptor (NMDA-receptor, see sub-
section NMDA receptor), as the most probable sites
of action.
The membrane hypothesis has not been com-
pletely abandoned. Some researchers postulate that
GAs act on the membrane molecules in the vicinity
of membrane protein molecules; this indirect action
of GAs changes the functions and properties of
these membrane proteins, and causes anaesthesia
(Cantor, 1997).
Drug classiﬁcation
Although the Meyer–Overton rule hinted at the pos-
sibility of a unitary mechanism of action of GAs,
research evidence is emerging that GAs are probably
not a single group of drugs all acting via the same
mechanism. A number of separate functional classes
of GAs are beginning to emerge.
Based on the putative site and mechanism of
action, GAs can be grouped into different classes.
Subsections GABAA receptors and NMDA receptor
will brieﬂy review the evidence for grouping GAs
into the following classes: (i) haloalkanes; (ii) pro-
pofol; (iii) etomidate; (iv) barbiturates; (v) neuros-
teroids; (vi) xenon and N2O (vii) alkanols. The
classiﬁcation of GAs is necessarily very ﬂuid,
because our knowledge of these drugs is limited. As
new results emerge, this classiﬁcation will change.
Neuronal pathways
Evidence is emerging that there are similarities but
also differences between sleep and anaesthesia
(Tung and Mendelson, 2003; Lydic and Baghdoyan,
2005), so understanding these pathways will help us
to locate the site of action of GAs.
Our knowledge of sleep–wakefulness pathways
began with the work of von Economo, who
observed the sleep–wakefulness states of brain-
damaged patients of encephalitis lethargica during
World War I (von Economo, 1917). He noted that
lesions of the posterior hypothalamus and rostral
midbrain led to a state of prolonged sleepiness,
while lesions of the pre-optic area and basal fore-
brain led to prolonged insomnia. He therefore sug-
gested that the region of the hypothalamus near the
optic chiasma contained sleep-promoting neurons,
but posterior hypothalamus contained neurons
which promoted the wakeful state (von Economo,
1929).
Over the years, his theory has been shown to
stand up reasonably well to scrutiny. The last few
decades have seen the discovery of the neuronal
circuitry which is responsible for sleep–wakefulness.
It is beyond the scope of this work to give a detailed
account of these pathways, so I shall concentrate on
how knowledge of them has made an impact on GA
research.
Put simply, there are two main pathways in
determining the sleep–wakefulness state (Saper
et al., 2001; Jones, 2005). The ascending arousal
pathway includes the pedunculo-pontine and
latero-dorsal tegmental nuclei which send projec-
tions to the thalamus, which are relayed and sent to
the cerebral cortices; this pathway also includes
ascending projections from the locus coeruleus,
raphé and tuberomammillary nucleus (TMN). The
descending sleep pathway includes projections from
the ventro-lateral pre-optic nucleus and the lateral
hypothalamic orexinogenic neurons to the TMN,
raphé, locus coeruleus and pedunculo-pontine and
latero-dorsal tegmental nuclei; in addition, lateral
hypothalamic neurons which release orexin also
innervate the cerebral cortices and the basal fore-
brain. Figure 3 shows the two pathways.
The possible sites of action of GAs can be found
along the ascending arousal pathway and the
descending sleep pathway. Three studies aimed to
deﬁne the effects of GAs on speciﬁc locations of the
pathways, and thus used a more direct approach.
Nelson et al. (2002) observed that the loss of right-
ing reﬂex caused by muscimol (a GABAA agonist
without GA activity), propofol and pentobarbital
was prevented by prior administration of subcuta-
neous administration of gabazine, a GABAA antago-
nist. To localize the site of action of the anaesthetics,
they used c-fos expression as an index of neuronal
activity, and found that muscimol, propofol or pen-
tobarbital increased c-fos expression in the ventro-
lateral pre-optic nucleus, but decreased c-fos
expression in the hypothalamic TMN. Lastly, the
authors micro-injected muscimol directly into the
TMN, and caused a loss of righting reﬂex. Micro-
injections of gabazine into the TMN could prevent
the hypnotic effect of propofol, and reduce the pen-
tobarbital effect. Sukhotinsky et al. (2007b) micro-
injected pentobarbital into the mesopontine
tegmental anaesthesia area of conscious rats and
showed that this drug reversibly induced an
anaesthesia-like state, with loss of consciousness.
This effect was attenuated by local pretreatment
with bicuculline (a GABAA antagonist). Because
pathways mediating immobility (Sukhotinsky et al.,
2005) and analgesia (Sukhotinsky et al., 2007a) also
project from the mesopontine tegmental anaesthe-
sia area, they suggested that the mesopontine teg-
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effect of GAs. Hentschke et al. (2005) compared the
effects of halothane, isoﬂurane and enﬂurane on the
activity of rat neocortical neurons in the whole
animal and also of brain slices of the rat neocortex.
They observed that the GAs decreased spontaneous
ﬁring of neurons to the same extent in both types of
experiments, for isoﬂurane and enﬂurane, and for
halothane at sub-clinical concentrations. For hal-
othane at clinical concentrations, the depression of
neocortical activity was different under the two con-
ditions. In all cases, this decrease in neocortical
activity was parallelled by enhancement of GABAA
receptor-mediated inhibition. The authors thus con-
cluded that the neocortical GABAA receptor could be
the site of GA action at least at lower concentrations
of the drugs.
There were other studies which administered
non-GA drugs and thus employed a more indirect
approach. For example, Ma et al. (2002) micro-
injected muscimol into the hippocampus of rats,
and showed that this decreased the dose of hal-
othane, isoﬂurane or propofol required to induce a
loss of righting reﬂex or a loss of tail-pinch response,
thus showing this part of the brain to be important
in mediating the loss-of-consciousness and analge-
sic effect of GAs. In a subsequent paper (Ma and
Leung, 2006), the authors further identiﬁed parts of
the limbic system to be involved in the action of
GAs. Alkire et al. (2007) micro-injected nicotine into
the central medial thalamus and found that the loss
of righting induced by sevoﬂurane was abolished.
These papers give us some glimpses of which
parts of the CNS could be involved in general ana-
esthesia, but none of them provides us with a con-
clusive picture of the pathways involved. Logically,
the GAs could be acting elsewhere, and that the
pathway studied was only a parallel pathway which
could override the pathway used by the GA. Care
should also be taken in the interpretation of micro-
injection experiments; Pilowsky (2004) has dis-
cussed the best practice expected of such work,
including the publication of experimental details,
but not all papers follow these guidelines rigorously.
However, these studies have demonstrated the
importance of the GABAA receptor, and it is to this
protein that we shall turn.
Protein receptor hypothesis: neurophysiology
The protein receptor hypothesis suggests that
the target of GAs is a protein. There are four main
candidates.
GABAA receptors. The family of GABAA receptors is
responsible for the majority of fast neuronal inhibi-
tion in the mammalian CNS, and is thought to be a
target of GAs. These oligomeric proteins belong to
the cys-loop family of ligand-gated ion channels
that includes the nicotinic acetylcholine, glycine
and 5HT3 receptors. The GABAA receptors are com-
posed of ﬁve subunits arranged pseudosymmetri-
cally around the integral anion channel (Nayeem
et al., 1994). The subunits, of which 19 have thus far
been identiﬁed, are separated into classes based on
their sequence similarity: there are six a-subunits;
three b; three g; three r; and single representatives of
d, e, q and p. The precise subunit isoform composi-
tion of the oligomer deﬁnes the recognition and
biophysical characteristics of the particular receptor
subtype. The most ubiquitous subtype, which
LC
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Raphé
TMN
VLPO
Thalamus
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Cerebral
cortices
BF LDT/PPT TMN
Raphé
VLPO
Figure 3
Diagrams showing the two major pathways determining the sleep–
wakefulness cycle. The upper panel shows the ascending arousal
pathway. The lower panel shows the descending sleep pathway,
where the orexinergic projections are shown in pink, and the other
projections in red. BF, basal forebrain; LC, locus coeruleus; LDT,
laterodorsal tegmental nuclei; PPT, pedunculopontine tegmental
nuclei; VLPO, ventrolateral pre-optic nucleus. Adapted from Hem-
mings et al. (2005).
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in the mammalian brain (Whiting, 2003), contains
two a1-, two b2- and a single g2-subunit (Farrar
et al., 1999). The GABAA receptors can be divided
into three structural domains: extracellular (EC)
domain, transmembrane (TM) domain and intracel-
lular (IC) domain. Figures 4 and 5 show a modelled
structure of the GABAA receptor, subtype
(a1)2(b2)2g2, taken from the work of Mokrab et al.
(2007).
The ﬁrst indication that GABA might be impli-
cated in the general anaesthetic response came from
Hales and Lambert (1991) who noted that propofol
potentiated the effect of GABA on its type A receptor
at concentrations similar to clinical ones, although
in the absence of GABA this drug was without effect.
Orser and her co-workers studied the effect of this
drug on GABAA receptors on mouse hippocampal
neurons, and found that propofol increased the Cl
-
conductance of the receptors in a dose-dependent
manner (Orser et al., 1994). Jones and Harrison
(1993), Moody et al. (1993) and Hall et al. (1994)
were the ﬁrst to note that the stereospeciﬁc action of
isoﬂurane in vivo was very similar to its action on the
GABAA receptor complex. Tomlin et al. (1998) dis-
covered that the stereoselective effects of etomidate
were similar to its action on this receptor.
Since then, there have been a large number of
studies linking the effect of GAs to altered function
of the GABAA receptors. All of them agree on one
point: GAs at clinical concentrations are without
effect unless GABA is also present (at higher concen-
trations, many drugs exert a direct effect on the
GABAA receptor, but this effect is unrelated to the
clinical use of GAs). Most of them also noted that
particular amino acid mutations caused changes in
GA effects. These results are summarized in Table 1,
and they show that the GAs acting on the GABAA
receptor could be divided into several groups,
depending on their binding site. The ﬁrst group, the
haloalkane GAs, all sharing overlapping sites near
all four transmembrane domains (TMDs) of the
a-subunits (Mihic et al., 1997; Jenkins et al., 2001;
2002), near Ser 297 and Ala 318 (Mokrab et al.,
2007). Propofol and etomidate, respectively, form
two separate groups, because they have different
binding patterns from the haloalkanes (Krasowski
et al., 1998), near the M2 and M3 domains of the
b-subunit. Propofol also affects the M4 domain of
the b-subunit (Richardson et al., 2007), but does not
appear to bind to the a-subunit (Bali and Akabas,
2004), while etomidate probably binds near the M1
domain of the a-subunit (Li et al., 2006). The barbi-
turates are in a class of its own; they require amino
acids in the M1 and M2 domains of the b-subunit
(Dalziel et al., 1999; Pistis et al., 1999), and loop D of
the extracellular domain of the a-subunit (Drafts
and Fisher, 2006) to exert their action. Neuroster-
oids should also be mentioned, although their use is
conﬁned to veterinary medicine; the drug probably
binds between the M1 and M4 domains of the
a-subunits (Hosie et al., 2006). Lastly, the alkanols
should be in a separate group because although it
acts on the GABAA receptor, it has wide-ranging
effects on other receptors (Pohorecky and Brick,
1988).
EC
TM
MA
Figure 4
Side view of a similarity model of the GABAA receptor, subtype
(a1)2(b2)2g2. The ﬁve subunits are shown in different colours. The
extent of the extracelular domains are labelled EC, that of the TMDs
TM and that of the helices of the intracellular domain are labelled
MA. Note that the intracellular domain consists of more than ﬁve
helices, but only these structures could be modelled. Taken from
ﬁgure 4 of Mokrab et al. (2007).
β2
γ2
α1
β2
α1
Figure 5
View of the same similarity model from the extracellular space
towards the intracellular space (the ‘top’ view). The ﬁve different
subunits are labelled. Taken from ﬁgure 5 of Mokrab et al. (2007).
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Point mutations on the GABAA receptor affecting the effect of GAs
Subunit Amino acid Drugs affected Reference
a1 T236 neurosteroids Hosie et al. (2006)
a1 Q241 neurosteroids Hosie et al. (2006)
a1 S270 eth, enﬂ Mihic et al. (1997)
a1 S270 eth Ueno et al. (1998)
a1 S270 isoﬂ, sevo, des Nishikawa and Harrison (2003)
a1 S291 eth, enﬂ Mihic et al. (1997)
a1 I406 chl Jenkins et al. (2002)
a1 F407 chl Jenkins et al. (2002)
a1 Y411 hal, isoﬂ Jenkins et al. (2002)
a1 A413 chl, isoﬂ Jenkins et al. (2002)
a1 T414 isoﬂ Jenkins et al. (2002)
a1 Y415 chl, hal Jenkins et al. (2002)
a1 L416 chl, hal Jenkins et al. (2002)
a1 N417 chl Jenkins et al. (2002)
a2 S270 isoﬂ Krasowski et al. (1998)
a2 S270 ether, enﬂ, mexyﬂ, sevo Krasowski and Harrison (2000)
a2 S270 isoﬂ, sevo, des Nishikawa and Harrison (2003)
a2 A291 isoﬂ Krasowski et al. (1998)
a2 A291 eth Ueno et al. (1998)
a2 A291 ether, enﬂ, mexyﬂ, sevo Krasowski and Harrison (2000)
a3 S294 isoﬂ Schoﬁeld and Harrison (2005)
a3 A315 isoﬂ Schoﬁeld and Harrison (2005)
a6 T69 pbb Drafts and Fisher (2006)
b1 T262 pbb Dalziel et al. (1999)
b1 S265 eth, enﬂ Mihic et al. (1997)
b1 S265 eth Ueno et al. (1998)
b1 S265 isoﬂ Krasowski and Harrison (2000)
b1 M286 eth, enﬂ Mihic et al. (1997)
b1 M286 pro, isoﬂ Krasowski et al. (1998)
b1 S265 etom Desai et al. (2009)
b1 S265 pro Krasowski and Harrison (2000)
b1 S290 pro, ppb Pistis et al. (1999)
b2 G219 pbb, pro Carlson et al. (2000)
b2 N265 etom Reynolds et al. (2003)
b2 M286 pro Watt et al. (2008)
b2 Y444 pro Richardson et al. (2007)
b3 N265 enﬂ, etom, pro Drexler et al. (2006)
b3 N289 pro, ppb Pistis et al. (1999)
b3 N290 etom Moody et al. (1997)
g2 S280 eth Ueno et al. (1998)
g2 L287 pro O’Shea et al. (2009)
g2 S301 eth Ueno et al. (1998)
Abbreviations used for the drugs: chl, chloroform; des, desﬂurane; enﬂ, enﬂurane; ether, diethyl ether; eth, ethanol; etom, etomidate; isoﬂ,
isoﬂurane; mexyﬂ, methoxyﬂurane; ppb, pentobarbital; pro, propofol; sevo, sevoﬂurane.
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site of GAs more directly. One is by mutating an
amino acid at the putative binding site to Cys, and
then measuring the reactivity of sulphydryl reagents
in the presence and absence of GAs. This approach
has identiﬁed a2-S270 of the TM2 domain of the
GABAA receptor to be near the binding site of enﬂu-
rane and isoﬂurane (Mascia et al., 2000), and
b2-M286 of the TM3 domain to be near the binding
site of propofol (Bali and Akabas, 2004). The other
method is to use a photo-afﬁnity analogue of the GA
and observe its binding; such analogues of haloal-
kanes (Eckenhoff et al., 2002) and etomidate
(Husain et al., 2003) have been synthesized. Li et al.
(2006) used
3H-azi-etomidate photo-afﬁnity label-
ling to identify a1-M236 and b3-M286 of the GABAA
receptor to be near the etomidate binding site.
Volume estimates were made on the putative GA
binding site. Jenkins et al. (2001) noted that differ-
ent haloalkane GAs were of different sizes, and that
mutations of the a-subunit Ser 270 could abolish
GABAA receptor modulation by these drugs. They
produced a series of mutants of this Ser 270 of dif-
ferent sizes, and were able to estimate the volume of
a proposed haloalkane binding site to be 250–
370 Å
3. Their results thus suggest a common site of
action for isoﬂurane, halothane and chloroform,
which is only large enough to accommodate one GA
molecule. Krasowski et al. (2001) used a similar
approach on the b2-M286, and estimated the pro-
pofol binding site to have a volume of about 200 Å
3.
These studies suffer from the fact that only recep-
tor responses were examined, but general anaesthe-
sia is a whole-animal effect, and an altered receptor
response cannot be used to demonstrate deﬁnitively
the effect of GAs. A transgenic animal approach
therefore was adopted by other researchers. Homan-
ics et al. (1997) engineered a mouse strain without
the a6 subunit, and found that the mutant animal
did not exhibit any altered response to GAs. Ugarte
et al. (2000) engineered a strain of knockout mice
lacking the b3 subunit of the GABAA receptor, and
found that they have lower pain thresholds; the
analgesic part of general anaesthesia could thus be
mediated by GABAA receptors. Cheng et al. (2006)
produced mutant mice lacking the a5 subunit of the
GABAA receptor, and found that etomidate retained
its amnestic effect but not the hypnotic effects.
Borghese et al. (2006) engineered mutant mice with
both S270H and L277A mutations in their GABAA
receptor a1-subunit, and showed that the response
of these mice to GABA was almost normal. Never-
theless, they exhibited reduced sensitivity to isoﬂu-
rane but not to halothane. In a subsequent paper,
Sonner et al. (2007) showed that these mice pos-
sessed altered loss of righting reﬂexes to gaseous
GAs; the drugs had no effects on the amnestic nor
the immobilizing effects on the mice. These results
are highly suggestive, but one must bear in mind
that functional compensation can occur in trans-
genic animals. Lastly, whole-animal electrophysi-
ological study described earlier (Nelson et al., 2002)
has linked molecular effects to whole-animal
effects.
The evidence for the involvement of the GABAA
receptor in GA effects, although circumstantial, is
thus quite strong, with a high probability that the
gaseous haloalkanes, etomidate and the barbiturates
interact with different regions of the a- and
b-subunits, while propofol binds to the b-subunit.
Propofol does not appear to bind to the the
a-subunit.
NMDA receptor. Glutamate is a neurotransmitter in
the CNS and acts on three classes of receptors
named after their selective agonists: NMDA, AMPA
and kainate. The NMDA receptor is a tetrameric
receptor (Behe et al., 1995; Premkumar and Auer-
bach, 1997; Laube et al., 1998). There are two
known classes of subunits, named NR1 and NR2, the
latter with four subtypes called NR2A to NR2D. Each
subunit consists of an extracellular amino-terminal
domain (ATD), an extracellular agonist-binding
domain (ABD), a TMD and a C-terminal intracellu-
lar domain (Wood et al., 1995; Paoletti and Neyton,
2007). NMDA receptors are slow-acting excitatory
receptors, with the activation process occuring on a
scale of tens to hundreds of milliseconds.
The structure of the NMDA receptor has not been
determined experimentally, but that of the AMPA
receptor is available (Sobolevsky et al., 2009). This
receptor consists of a large extracellular part which
comprises the ATD and ABD, and which displays a
twofold axis of symmetry. The TMD, on the other
hand, has a fourfold axis of symmetry centred
around the ion channel. Figures 6 and 7 show the
structure of this AMPA receptor. The NMDA receptor
is believed to possess a similar structure.
The NMDA receptor probably mediates the effect
of xenon (de Sousa et al., 2000) and N2O (Jevtovic ´-
Todorovic ´ et al., 1995). Franks et al. (1998) showed
that xenon reduces the NMDA-activated currents in
hippocampal neurons, and Dickinson et al. (2007)
identiﬁed a putative binding site using single-cell
experiments and modelling. Using a transgenic
approach, Sato et al. (2005) showed that the sensi-
tivity to N2O was signiﬁcantly reduced in knockout
mice lacking the NR2A subunit (coded for by the
e1-subunit gene) of the NMDA receptor, but the
effects of sevoﬂurane were unaffected. This remains
the most convincing result to date which implicates
the NMDA receptor in the action of nitrous oxide,
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tional compensation in transgenic animals. Haloal-
kanes also reduce the NMDA-activated currents in
this receptor, but their effects are less prominent
than those on the GABAA receptor (Martin et al.,
1995; Hollmann et al., 2001; Solt et al., 2006), so the
role of haloalkanes on this receptor in anaesthesia is
unclear.
Glycine receptor. Glycine, like GABA, is an inhibi-
tory neurotransmtter. The glycine receptor is also a
cys-loop receptor, so its structural motifs are similar
to those of the GABAA receptor. There are two classes
of subunits for this receptor, a and b. The a-subunits
consist of four subtypes, a1t oa4 (Matzenbach et al.,
1994), while only one subtype exists for the
b-subunit (Handford et al., 1996). On agonist
binding, the glycine receptor opens the central ion
channel to allow chloride ions through; it is usually
part of an inhibitory synapse (Curtis et al., 1967;
1968). Extensive work has been published on the
glycine receptor which showed the modulatory
effect of GAs on this receptor (Mihic et al., 1997; Ye
et al., 1998; Yamakura et al., 1999; Krasowski and
Harrison, 2000; Beckstead et al., 2001; 2002; Ahrens
et al., 2008).
Ye et al. (2009) experimented on rats and showed
that strychnine abolished the loss of righting reﬂex
induced by ethanol, but not that induced by ket-
amine, and concluded that the glycine receptor was
implicated in ethanol effects. Nguyen et al. (2009)
performed experiments on whole rats and rat brain
slices to show that propofol potentiated the effect of
glycine on its receptor, and that this effect was
blocked by strychnine. However, they used a high
concentration of propofol capable of direct activa-
tion of the glycine receptor. Further studies are
needed to establish the exact role of this receptor in
GA effects, and also to identify the location of these
receptors on the sleep–wakefulness pathway.
Potassium channels. It has been known for a long
time that GAs hyperpolarize neurons by acting on
the potassium currents (Nicoll and Madison, 1982;
Berg-Johnsen and Langmoen, 1986; 1987; Franks
and Lieb, 1988; Sugiyama et al., 1992). One of the
putative targets of GAs was identiﬁed as the two-
pore-domain K
+ channel. These K
+ channels contain
four TMDs and two ion channels in tandem (Fink
et al., 1996; Lesage et al., 1996; Duprat et al., 1997;
Fink et al., 1998).
Tissue studies have been performed on these K
+
channels. Patel et al. (1999) examined TASK and
TREK-1, and found that TREK-1 was activated by
chloroform, diethyl ether, halothane and isoﬂurane,
while TASK was activated by halothane and isoﬂu-
rane. Liu et al. (2004) engineered human TRESK
channels into the Xenopus oocyte, and noted that
their outward currents were potentiated 1.5- to
3-fold by different haloalkane GAs. Gruss et al.
(2004) expressed TREK-1 channels on HEK-293 cells
and showed that TREK-1 currents were enhanced by
nitrous oxide, xenon, cyclopropane and halothane.
Andres-Enguix et al. (2009) cloned a TASK channel
from the mollusc Lymnaea stagnalis and discovered
that it was preferentially activated by (+)-isoﬂurane;
this was also observed in mice (Harris et al., 1992)
and rats (Lysko et al., 1994).
Heurteaux et al. (2004) engineered a transgenic
Trek -/- mouse and found that the loss of righting
reﬂex was observed in lower concentrations of chlo-
roform, halothane, sevoﬂurane and desﬂurane in
the mutant mouse than in the wild type. This result
is highly suggestive, but one must bear in mind that
functional compensation can occur in transgenic
animals. Further studies are required to establish the
exact role of these K
+ channels in GA action.
TMD
ABD
ATD
Figure 6
Side view of the AMPA receptor, showing the ATD, ABD and TMD.
The four subunits are shown in different colours. Atomic coordinates
of the intracellular domain are not available. Drawn from the PDB
data set 3KG2 (Sobolevsky et al., 2009).
Figure 7
View of the AMPA receptor from the extracellular space towards the
intracellular space (the ‘top’ view).
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shown to bind GAs (Forman et al., 1995; Zhang
et al., 1997; Pratt et al., 2000; Yamashita et al., 2005),
but all these studies only show parallelism of drug
association with GA effect in cells or tissues, and
none of them could directly link binding to whole-
animal GA effects; general anaesthesia, by deﬁni-
tion, can only be observed in a whole animal, not in
brain slices or cell cultures.
Protein receptor hypothesis:
molecular mechanisms
Surprisingly, little has been written on actual
molecular mechanisms involved in general anaes-
thesia. The lack of a structure of any of the putative
receptors at atomic resolution is the main stumbling
block to further progress. One way forward is to
model the structure of these proteins using similar-
ity modelling methods. Since the publication of the
4 Å structure of the nAChR (Unwin, 2005), PDB
code 2BG9, its coordinates have been used for a
number of GABAA receptor models (Ernst et al.,
2005; Mokrab et al., 2007) where GAs were docked
to the modelled structure (Figure 8). The problem
with these results is that they have yet to await
experimental conﬁrmation. None of these studies
have attempted to propose a molecular mechanism
of action.
Horenstein et al. (2001) produced Cys mutants of
amino acids of the M2 helix of an a3b2 subtype of
the GABAA receptor, and examined the possibility
of forming disulphide bridges in the presence or
absence of GABA, under reducing or oxidizing con-
ditions. They found that 6′ disulphide bridges
formed between adjacent subunits in the open, but
not the closed state. They reasoned that this implies
the M2 helices rotate on activation by the agonist.
They engineered ﬁve different mutants of the
(a1)2(b2)2g subtype of the GABAA receptor, and
attached ﬂuorophores to the mutated Cys. They dis-
covered that there was a closure of the GABA-
binding cavity at the subunit interface (Muroi et al.,
2006). Using the same technique, they identiﬁed
residues in the a1 and b2 pre-M1 region important
in gating (Mercado and Czajkowski, 2006). They
also investigated the effect of pentobarbital on some
of these mutants (Muroi et al., 2009), and noted that
at concentrations which produced clinical anaesthe-
sia, pentobarbital changed the ﬂuorescence of the
probe attached to the b2-K274C mutant Cys when
no g2 subunits were present in the receptor. GABA,
on the other hand, elicited a ﬂuorescence change
of the opposite sign. Thus, it appears the channel-
opening mechanisms used by GABA and by
pentobarbital are different. One should note that all
these studies attached mutant Cys to large ﬂuores-
cent groups, so the mutation and steric effects
should be borne in mind when interpreting the
results.
A completely different direction was taken by
Roth et al. (2008), who suggested that the gating of
ion channels was caused by the formation and dis-
apperance of bubbles. They also suggested that
xenon caused anaesthesia by inserting into the ion
channel, and thus increasing the probability of
bubble formation, and that high pressure reverses
the effect of xenon. Using simple models, they pro-
duced results which showed the feasibility of this
hypothesis. Unfortunately, they still viewed the
Meyer–Overton rule as a useful guide to the unitary
mechanism of GA action, while we know that many
drugs violate the Meyer–Overton rule and the
unitary mechanism is probably no longer tenable
(Mullins, 1954; Cantor, 2001). This hypothesis is
unable to account for the stereospeciﬁcity of GAs. It
would seem that it might be unable to account for
the effect of GAs of larger sizes, such as diethyl ether,
isoﬂurane or enﬂurane.
Thus, so far, no concrete molecular mechanism
has been proposed for GA action. The main difﬁ-
culty of proposing a hypothesis for GA action is that
we still do not quite know how the putative GA
receptors open their ion channels on agonist
binding, let alone how this opening can be modu-
lated. Until and unless this is established, it would
be impossible to suggest a falsiﬁable hypothesis of
how GAs work.
TM1 TM2
TM4
Leu 259 Ser 297
Ala 318
Figure 8
View of two possible binding positions of halothane to the
a1-subunit of a model of the GABAA receptor. The transmembrane
helices, labelled TM1 to TM4, are shown in green. The carbon atoms
of halothane are shown in blue. Amino acids shown to be involved in
binding are shown in magenta and labelled. Taken from ﬁgure 13 of
Mokrab et al. (2007).
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It is obvious from previous research that the mem-
brane is involved in GA effects, but it is unclear how.
Research on this front can be divided under three
headings: where the GAs go inside the membrane,
what they do to the membrane and how all this
relates to GA effects.
Previous experiments have shown that GAs par-
tition to the area of the membrane near the interfa-
cial and non-polar regions of the membrane
(Yokono et al., 1989; Tang et al., 1997; Feller et al.,
2002; Carnini et al., 2004). Results from atomistic
molecular dynamics simulations were consistent
with these results (Tu et al., 1998; Koubi et al., 2002).
Simulations basically create an artiﬁcal world, and
use this artiﬁcial world to examine the properties of
the system under study. With current supercomput-
ers, it is possible to perform atomistic molecular
dynamics simulations of membrane protein com-
plexes consisting of hundreds of thousands of
atoms, and for tens of nanoseconds of simulated
time. The structural and dynamic properties of the
system can be obtained from the trajectory, and free
energy changes of different processes evaluated
(Chau, 2006).
Cantor (1997; 2001) suggested that the lateral
pressure proﬁle in a membrane was not uniform,
GAs perturbed this pressure proﬁle and this shifted
the equilibrium of the conformation change of pro-
teins; this was the basis of GA effects. Griepernau
and Böckmann (2008) performed molecular dynam-
ics simulations of a DMPC bilayer at 1 and 1000 atm
pressure, and explored the effect of dissolving four
types of 1-alkanols in them. They showed that the
local lateral pressure proﬁle changed on addition of
1-alkanols, but this change was not reversed at high
pressure. Nevertheless, asuming a bent helix model
for the target protein, they found that high pressure
would reverse the effect of 1-alkanols on the
protein.
Although this hypothesis provides an explana-
tion for the GA molecules which do not obey the
Meyer–Overton rule, it has a number of weaknesses.
Firstly, the lateral pressure of a membrane is not
uniquely deﬁned; it cannot be measured, although
some indication of the pressure changes could be
obtained from indicator molecules (Templer et al.,
1998; Kamo et al., 2006). So almost all the work
supporting it come from simulations. Secondly, the
lateral pressure effect does not correlate with the GA
effect. Simulations showed that the alkanols had
little effect on membrane lateral pressure (Terama
et al., 2008), but the effect of sterols on membrane
lateral pressure was much greater (Ollila et al.,
2007). This hypothesis has not explained why most
sterols are not anaesthetics, but ethanol is. Thirdly,
this work is very context dependent. The work of
Griepernau and Böckmann (2008) goes some way
towards incorporating pressure reversal with GA
effects mediated via lateral pressure proﬁles, but it
also shows that the applicability of this hypothesis
depends crucially on the mechanism of action of
the target protein. Their work was partly carried out
at 1000 atm, which is beyond where pressure rever-
sal takes place, so its relevance is doubtful. Lastly,
the hypothesis is extremely sparse on essential
details, such as which protein(s) would be the
intended target. Without such information, this
hypothesis could only be tested for its feasibility,
and is not really a falsiﬁable hypothesis.
Membrane simulations are now developing in
three main directions. In one direction is the devel-
opment of coarse-grain simulations to study the
interaction of GAs and membranes (Pickholz et al.,
2005). These simulations treat four atoms as one
sphere, while in classical molecular dynamics simu-
lations, each atom is treated as one sphere. This
allows us to access longer timescales and larger
length scales, but care must be taken to treat the
solvents correctly (Bock et al., 2007).
In the second direction, peptides or proteins are
placed in membranes, and classical molecular
dynamics simulations are performed. Tang and Xu
(2002) placed gramicidin in a hydrated DMPC
bilayer and showed that halothane profoundly
changes the dynamics of the protein. Vemparala
et al. (2006) placed the transmembrane helices of
the nAChR a- and d-subunits in a hydrated DOPC
bilayer, and showed that halothane signiﬁcantly
altered protein dynamics; similar results were
obtained on the KirBac1.1 potassium channel (Vem-
parala et al., 2008). Combined experiment and
simulation studies have also been carried out on
‘designer’ proteins (Cui et al., 2008; Ma et al., 2008;
Liu et al., 2009; Strzalka et al., 2009; Zou et al.,
2009). However, these peptides/proteins are not true
GA targets, so whether these results are relevant to
general anaesthesia is unknown.
The work of Chau et al. (2007; 2009) took a dif-
ferent direction by going back to pressure reversal.
Using molecular dynamics simulations, they
showed that, at 200 atm, halothane molecules
inside a DMPC bilayer tended to aggregate. The for-
mation of these clusters was reversible on taking the
pressure back to 1 atm. Drawing on previous work
by Jenkins et al. (2001) which showed that the
binding site for haloalkane GAs in the GABAA recep-
tor could only accommodate one molecule, they
proposed that pressure reversal occurred when hal-
othane aggregated, so fewer monomeric halothane
was available to bind to the putative binding site.
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membrane plays an important role in general
anaesthesia, it is a pharmacokinetic effect, not a
pharmacodynamic effect. The weakness of this
hypothesis is that they used a concentration of hal-
othane three times that of clinical concentration.
There is as yet no experimental veriﬁcation of this
effect; only very delicate neutron reﬂectometry and
X-ray scattering experiments would be capable of
verifying the aggregation hypothesis. It is also not
known if this effect is peculiar to the halothane/
DMPC combination or if it is a more general effect.
Future directions
There are a number of obstacles to be obviated
before further progress is possible.
The ﬁrst problem concerns neural pathways. Our
understanding of what anaesthesia is in terms of
neurology is still incomplete. There have been per-
suasive studies showing the involvement of differ-
ent protein receptors on different pathways.
However, logically, the GAs could be acting else-
where, and that the pathway studied was only a
parallel pathway which could override the pathway
used by the GA. We would need some more deﬁni-
tive demonstration of the pathway and receptors
involved in anaesthesia. This is particularly perti-
nent in terms of the different effects of GAs: loss of
consciousness, muscle relaxation, amnesia and anal-
gesia are thought to be modulated by different
receptor proteins (Reynolds et al., 2003; Cheng
et al., 2006; Irifune et al., 2007; Rau et al., 2009).
However, different receptor proteins reside on dif-
ferent parts of the CNS, especially in the case of the
different GABAA receptor subtypes (Barnard et al.,
1998; Pirker et al., 2000). Some are synaptic mediat-
ing classical phasic inhibition, while others are
extra-synaptic mediating tonic inhibition (Belelli
et al., 2009). Preliminary results suggest that differ-
ent GAs might affect different receptor subtypes
(Kitamura et al., 2003; Bieda and MacIver, 2004).
How are the different receptor subtypes distributed
on different pathways, and how does this distribu-
tion, and their diverse functions, relate to the dif-
ferent effects of the GAs? Novel electrophysiological
techniques, in vivo genetics and high-resolution
brain imaging methods might help us to answer
some of these questions.
At the molecular level, one needs to deﬁne the
structure and mechanism of action of the putative
receptors, namely the GABAA receptor, NMDA
receptor, glycine receptor and possibly the two-pore
potassium channels. The structures of these recep-
tors have not been determined, so our knowledge of
their structures is inferred from mutagenesis, photo-
afﬁnity labelling experiments and modelling. This is
not a desirable state of affairs, as these indirect
methods have limited accuracy. There have been
suggestions that the development of an X-ray free
electron laser could revolutionize the determination
of protein structures, by using an intense but ultra-
short light pulse to obtain data (Neutze et al., 2004).
It would be interesting to see if this exciting new
method can be extended for the determination of
membrane proteins.
Without more accurate and precise information
about their sturctures, it would be extremely difﬁ-
cult to delineate the mechanism of action of these
proteins, and how their functioning is altered in the
presence of GAs. Most of the studies on ion channel
function have only proposed which amino acid is
important for the function; they do not propose a
precise mechanism of how ligand binding increases
the probability of the ion channel opening via the
changes of certain dihedral angles, how the ion
hydration changes as it traverses the ion channel
and how GAs alter the movements brought about by
ligand binding. Some scientists have suggested some
notions of how GAs would change protein move-
ment, but the suggested mechanism is so vague as to
be unfalsiﬁable. This is where spectroscopy might
conceivably be of help.
Spectroscopy is the study of the absorption or
emission of electromagnetic radiation by molecules.
Spectroscopic experiments provide us with the fre-
quencies of the radiation, and the amount of radia-
tion absorbed or emitted, by the sample. In the case
of protein studies, the radiation absorbed by a
vibrating C=O bond in the peptide link is in the
mid-infrared range (frequency around 5 ¥ 10
13 Hz).
When the secondary structure of the protein
changes, this so-called amide (I) absorption band
changes, and the radiation absorbed changes, and
from this we can infer the change in protein struc-
ture. Thus, infrared spectroscopy is of use in study-
ing protein conformation changes. It has
contributed to our understanding of the structural
changes of the protein rhodopsin II when it binds
the cofactor retinal and transports ions (Jiang et al.,
2008), and those of the MelB protein when it binds
the ligand melibiose (Lórenz-Fonfría et al., 2009).
Coupled with protein structure data, this method
can be developed to deﬁne protein movement on
ligand binding, and how this movement is changed
by the presence of GAs. As an aside, one could add
that the pre-existent data seem to favour a ‘door
wedge’ hypothesis for GA action. At clinical doses,
GAs only affect the putative receptor if an agonist is
already acting on the receptor; on their own, the
drugs do not affect the protein. The GA molecule
thus acts like a door wedge. It does not open the
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mechanistic details of this hypothesis remains to be
demonstrated, and infrared spectroscopy can be a
useful tool. A prediction of this hypothesis is that
there are no antagonists of GAs, and to date, none
has been discovered.
Lastly, there is always the problem of pressure
reversal. Little of the protein receptor work has
approached this peculiar property of GAs. Is it an
effect at the level of the whole CNS (Halsey, 1982;
Little and Thomas, 1986), or is it an effect at the
molecular level (Trudell et al., 1973a,b; 1975; Chau
et al., 2007; 2009)? Recent research has swung
towards a protein receptor for GAs, and the evidence
isquitepersuasive.However,thereisalsoexperimen-
tal evidence which suggests the importance of the
membrane in GA action, especially in pressure rever-
sal. Work is needed to unravel this part of the GA
puzzle.
Conclusions
GAs have been in use for over one and a half cen-
turies, but their mechanism of action still eludes
pharmacologists. We now understand a bit more
than we did before; the unitary mechanism hypoth-
esis has given way to the multiple-receptor hypoth-
esis. Unfortunately, this makes the whole subject
even more complex.
In this paper, I have reviewed the recent
advances, described the gaps in our knowledge and
suggested what is needed to arrive at a molecular
mechanism for GA action. GA research has so far
lacked a clear, falsiﬁable hypothesis. In this work, I
have spelt out the ‘door wedge hypothesis’ which
we should try to falsify or demonstrate. Historically,
most biomedical advances have been contingent
upon advances in physics and chemistry, and the
application of those techniques in biology and
medicine. I have thus brieﬂy reviewed some of the
relevant physical and chemical methods, and
explored the opportunities these methods can offer
for investigating GA effects at the molecular level.
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